Etrasimod CD Trial


A worldwide, Phase 2b trial evaluating etrasimod – an oral, selective, sphingosine 1 phosphate (S1P) receptor modulator – for the treatment of moderately to severely active Crohn’s disease.

Addressing the Root of CD. Join Cultivate.

Patients may be able to take part in the clinical program if they*:

  • Are 18 to 80 years of age
  • Have been diagnosed with Crohn’s disease for at least 3 months
  • Have previously been on a Crohn’s disease treatment which did not work or which you could not tolerate
  • Are currently experiencing an active flare (A flare usually consists of symptoms like frequent bowel movements or diarrhea, bloody stool, and/or abdominal pain. You may also experience fatigue, a lack of appetite, and weight loss.)

For more information please visit

*Other eligibility criteria may apply